Edwards lifesciences reports first quarter results

Irvine, calif.--(business wire)--edwards lifesciences (nyse: ew) today reported financial results for the quarter ended march 31, 2024. highlights and outlook q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion q1 tavr sales grew 6%; constant currency sales grew 8% adjusted for billing days q1 tmtt sales grew 75% q1 eps of $0.58; adjusted1 eps of $0.66 raising 2024 sales guidance to the high end of previous 8 to 10%1 range raising full-year 2024 sales guidance for tmtt.
EW Ratings Summary
EW Quant Ranking